Program

PO1-2-72

Use of Mineralocorticoid Receptor Antagonists in Real-world Patients with Heart Failure and Reduced Ejection Fraction: HIJ-HF II study

[Speaker] Atsushi Suzuki:1
[Co-author] Yuko Matsui:1, Kimiko Nagara:1, Tsuyoshi Shiga:1, Nobuhisa Hagiwara:1
1:Cardiology, Tokyo Women's Medical University, Japan

Mineralocorticoid receptor antagonists (MRAs) improve outcomes in heart failure with reduced ejection fraction (HFrEF), but may be under-utilized in contemporary clinical practice. The aim of this study was to assess predictors of MRAs non-use in HFrEF patients. We studied 331 HFrEF patients (EF<40%) from a multicenter hospital-based cohort consisted of hospitalized HF patients between 2013 and 2014. 217 patients (66%) were receiving MRAs. There was a significant lower rates of MRAs non-use in patients with ischemic heart disease, without implantable cardioverter defibrillator (ICD) receiving, BNP less than 500 pg/ml and without angiotensin-converting-enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB). MRAs remain underused in HFrEF patients (Figure). We should understand the indications and benefits of MRAs in appropriate HFrEF patients suggested in guideline.

Advanced Search